Psilocybin use among U.S. adults has surged—doubling since Denver decriminalized the psychedelic in 2019—highlighting a striking shift in social norms and public health needs. This trend underscores evolving views on “magic mushrooms”, policy implications, and the urgent need for data-driven regulation and risk mitigation.
A recent study published in the Annals of Internal Medicine, led by researchers at the University of Colorado Anschutz Medical Campus and Rocky Mountain Poison and Drug Safety, reveals compelling trends:
These findings align with the timeline when Denver became the first U.S. city to decriminalize psilocybin in 2019—an early signal of changing cultural and regulatory landscapes.
Decriminalization appears to have reduced stigma and perceived risk, making psilocybin more accessible. While growing interest stems partly from media coverage of its mental health potential (e.g., depression, PTSD), this normalization has outpaced structured public education or safety frameworks.
The spike in poison control calls—particularly among minors—raises alarm about unintended access, accidental ingestion, and insufficient awareness. The discrepancy between poison center data and near-absent emergency department reporting highlights major gaps in medical tracking systems.
Policymakers now face a crossroads: balancing emerging therapeutic promises of psilocybin with public safety. While supervised use in treatment contexts shows hope, the current trend toward self-use needs proactive frameworks, including education, safe-use guidelines, and enhanced surveillance.
Denver’s 2019 policy sparked a wave: cities like Oakland, Santa Cruz, and Seattle followed suit—with Oregon and Colorado later permitting regulated therapeutic access under structured programs.
A separate RAND Corporation survey in 2024 confirms psilocybin is the most widely used psychedelic among U.S. adults—3.1% reporting past-year use and ~12% lifetime use.
